BPC-157

In animal work, BPC-157 appears to promote healing by encouraging new blood-vessel growth and modulating growth-factor and nitric-oxide signaling at injury sites. The parent 'Body Protection Compound' protein is not well characterized in protein databases, so the peptide is best described as a synthetic fragment.

Sequence: GEPPPGKPADDAGLVA 15-residue synthetic peptide (note the three consecutive prolines). No UniProt entry exists for the isolated peptide.

One claim per card, each with its own tier and source. Tiers 1 and 2 are human data. Tiers 3 and 4 are not yet.

• Accelerated tendon, muscle, and gut-lining healing in rodent injury models.

  T3Preclinical
  [1]Chang et al., 2011 (J Appl Physiol) — via PMC(opens in a new tab)

• No completed placebo-controlled human efficacy trial; the first Phase 2 RCT is only recently registered.

  T4Emerging
  [2]Safety of intravenous BPC-157 in humans (PubMed)(opens in a new tab)

1. [1]Chang et al., 2011 (J Appl Physiol) — via PMC (opens in a new tab)
2. [2]Safety of intravenous BPC-157 in humans (PubMed) (opens in a new tab)

• TB-500T1Established

  Synthetic actin-binding fragment of thymosin β4

  The migration-and-angiogenesis peptide behind the recovery hype.

  1 of 3 claims human-tested · 2 references · Research-only

• KPVT3Preclinical

  Anti-inflammatory tripeptide

  The three-residue tail of α-MSH that calms inflammation.

  No human data yet · 2 references · Research-only

• GHK-CuT2Clinical

  Copper-binding tripeptide

  The copper peptide that actually earned its place in skincare.

  1 of 2 claims human-tested · 2 references · Research-only